FDA
-
-
-
-
-
-
-
Omeros Corporation to Announce Fourth Quarter and Full-Year 2025 Financial Results on March 31, 2026
-
-
-
-
-
-
-
Omeros stock soars after FDA approves first treatment for TA-TMA
-
-
-
-
-
-
-
Omeros publishes study showing survival benefits of narsoplimab treatment
-
-
-
-
-
-
-
Omeros prices $22 million direct offering at 14% premium
-
-
-
-
-
-
-
Omeros (OMER) Announces Agreements to Acquire $80.5 Million of its Convertible Senior Notes Due 2026
-
-
-
-
-
-
-
Omeros Corporation Reports Fourth Quarter and Year-End 2024 Financial Results
-
-
-
-
-
-
-
Omeros Corporation Announces Availability on its Website of Materials Accompanying Narsoplimab Presentations at the 2025 Tandem Meetings
-
323,123 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All

